SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY

Almost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. N. Gorshkova, E. A. Vasilenko, S. V. Tillib, I. V. Astrakhantseva
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2016
Materias:	single-domain antibodies сamel antibodies nanoantibodies vhh bi-specific antibodies bioengineered drugs Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/0d2b367f078848c98022a2764ff53ec5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d2b367f078848c98022a2764ff53ec5
record_format	dspace
spelling	oai:doaj.org-article:0d2b367f078848c98022a2764ff53ec52021-11-18T08:03:45ZSINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY1563-06252313-741X10.15789/1563-0625-2016-6-505-520https://doaj.org/article/0d2b367f078848c98022a2764ff53ec52016-12-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1131https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAlmost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called the single domain antibody (sdAb), “nanobody” or “nanoantibody”. The single-domain antibodies and their derivatives have been widely used in the field of biology, toxicology and medicine offering new opportunities for diagnosis and treatment of cancer, autoimmune diseases, infectious diseases, and for toxin neutralization. This review focuses on latest researches in the field and concerns some prospectives for creation of nanoantibody-based diagnostic and therapeutic drugs.E. N. GorshkovaE. A. VasilenkoS. V. TillibI. V. AstrakhantsevaSPb RAACIarticlesingle-domain antibodiesсamel antibodiesnanoantibodiesvhhbi-specific antibodiesbioengineered drugsImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 18, Iss 6, Pp 505-520 (2016)
institution	DOAJ
collection	DOAJ
language	RU
topic	single-domain antibodies сamel antibodies nanoantibodies vhh bi-specific antibodies bioengineered drugs Immunologic diseases. Allergy RC581-607
spellingShingle	single-domain antibodies сamel antibodies nanoantibodies vhh bi-specific antibodies bioengineered drugs Immunologic diseases. Allergy RC581-607 E. N. Gorshkova E. A. Vasilenko S. V. Tillib I. V. Astrakhantseva SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY
description	Almost 20 years ago, a unique class of antibodies devoid of L chains was discovered in Camelidae blood serum. Only one variable domain is responsible for antigen recognition in these unusual antibodies. A recombinant protein, which is analogue to such antigen-recognizing variable domain was called the single domain antibody (sdAb), “nanobody” or “nanoantibody”. The single-domain antibodies and their derivatives have been widely used in the field of biology, toxicology and medicine offering new opportunities for diagnosis and treatment of cancer, autoimmune diseases, infectious diseases, and for toxin neutralization. This review focuses on latest researches in the field and concerns some prospectives for creation of nanoantibody-based diagnostic and therapeutic drugs.
format	article
author	E. N. Gorshkova E. A. Vasilenko S. V. Tillib I. V. Astrakhantseva
author_facet	E. N. Gorshkova E. A. Vasilenko S. V. Tillib I. V. Astrakhantseva
author_sort	E. N. Gorshkova
title	SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY
title_short	SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY
title_full	SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY
title_fullStr	SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY
title_full_unstemmed	SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY
title_sort	single domain antibodies and bioengineering drugs on their basis: new opportunities for diagnostics and therapy
publisher	SPb RAACI
publishDate	2016
url	https://doaj.org/article/0d2b367f078848c98022a2764ff53ec5
work_keys_str_mv	AT engorshkova singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy AT eavasilenko singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy AT svtillib singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy AT ivastrakhantseva singledomainantibodiesandbioengineeringdrugsontheirbasisnewopportunitiesfordiagnosticsandtherapy
_version_	1718422395768799232

SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY

Ejemplares similares